2
1M
1
0.50
- Areas of investment
Summary
Among the most popular portfolio startups of the fund, we may highlight Defymed. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Diabetes.
The top activity for fund was in 2011. The fund is constantly included in less than 2 deals per year. Deals in the range of 1 - 5 millions dollars are the general things for fund.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the CTTM, startups are often financed by CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te), Statice, Emertec Gestion. The meaningful sponsors for the fund in investment in the same round are CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te), Statice, Emertec Gestion. In the next rounds fund is usually obtained by Emertec Gestion, CeeD (Centre Europu00e9en d'u00e9tude du diabu00e8te), Cap Innov'Est.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Follow on index
- 0.50
- Investments by industry
- Medical Device (2)
- Diabetes (2)
- Investments by region
-
- France (2)
- Peak activity year
- 2011
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Defymed | 27 Oct 2015 | Medical Device, Diabetes | Seed | 2M | Grand Est, Strasbourg, France |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.